Cabaletta Bio, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Cabaletta Bio, Inc. | CABA - NASDAQ |
$14.00-$16.00 | $11.00 | $9.00 | 6.8 million | 10/25/2019 |
| Morgan Stanley, Cowen, Evercore ISI | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-09-30 Terms Added 2019-10-16 | ||||||
Cabaletta Bio, Inc. Quote & Chart - Click for current quote - CABA
IPO Boutique aggregates information on public companies and private companies, such as "CABA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Cabaletta Bio, Inc. (adapted from Cabaletta Bio, Inc. prospectus):
They are a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "CABA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.